-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLS-0071 in Hypoxic-Ischemic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLS-0071 in Hypoxic-Ischemic Encephalopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLS-0071 in Hypoxic-Ischemic Encephalopathy Drug Details: RLS-0071 (PIC1-01) is under development...
-
Product Insights
Hypoxic-Ischemic Encephalopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypoxic-Ischemic Encephalopathy - Drugs In Development, 2023’, provides an overview of the Hypoxic-Ischemic Encephalopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypoxic-Ischemic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Encephalopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Encephalopathy - Drugs In Development, 2023’, provides an overview of the Encephalopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2023’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Graft Versus Host Disease (GVHD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Drugs In Development, 2023’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Bone Marrow Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Bone Marrow Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADG-126 in Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADG-126 in Uveal Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADG-126 in Uveal Melanoma Drug Details: ADG-126 is under development for the...
-
Product Insights
Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Its symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching, and muscle weakness. The Encephalopathy pipeline market research report provides comprehensive information on the therapeutics under development for Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RLS-0071
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RLS-0071 Drug Details RLS-0071 (PIC1-01) is under development for the treatment of neonatal hypoxic-ischemic...